Login to Your Account


Chimerix quits Ebola trials as Hemispherx gets started

By Michael Fitzhugh
Staff Writer

Monday, February 2, 2015

Chimerix Inc.'s decision Friday to cancel trials of its antiviral brincidofovir to protect against Ebola in the face of declining numbers of new infections, and thus dwindling numbers of test subjects, brought into sharp relief the hard choices small companies need to make when choosing to develop experimental treatments for neglected tropical diseases.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription